Plozasiran sodium

普乐司兰钠

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NamePlozasiran sodium
Drug Alias NamePlozasiran瑞达普REDEMPLOARO-APOC3VSA001 +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceApolipoprotein C-III degraders
TargetsApolipoprotein C-III
Therapy Area/IndicationsHypertriglyceridemiaDyslipidemiasHyperlipoproteinemia Type I +[4] 
Global Approved IndicationsHyperlipoproteinemia Type I
Approved Indications in ChinaHyperlipoproteinemia Type I
Original Approved Country/TerritoryUnited States
Original Approved Date2025/11/18
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesArrowhead Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesVisirna Therapeutics (Suzhou) Co LtdSanofiArrowhead Pharmaceuticals Inc
Inactive CompaniesVisirna Biotechnology (Shanghai) Co LtdVisirna Therapeutics HK Ltd
Active IndicationsHypertriglyceridemiaDyslipidemiasHyperlipoproteinemia Type I +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG